ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CK-586

Also written as “CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)” and “CK-4021586”.

Its studies are mostly in Heart Failure, led by Cytokinetics.

Furthest: phase 2, since Jan 21, 20252 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cytokinetics21 open or runningphase 2since Jan 21, 2025May 17, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT05877053 · 102 enrolled · United States
  2. Jan 21, 2025Phase 2 study in Heart FailureNCT06793371 · 60 planned · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06793371Heart Failure · United States2RecruitingSep 202660
NCT05877053Healthy Participants · United States1CompletedNov 20, 2024102

How it is read

Names in the registry

  • “CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)”, 1 entry
  • “CK-4021586”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.